Article
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
The European journal of health economics : HEPAC : health economics in prevention and care - 1 Jan 2018
Restelli Umberto, Alberti Alfredo, Lazzarin Adriano, Bonfanti Marzia, Nappi Carmela, Croce Davide
Abstract excerpt
The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.